Asche CV et al. |
Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States. |
2016 Mar-Apr |
Value Health |
pmid:27021759
|
Fallen RS and Gooderham M |
Ingenol mebutate: an introduction. |
2012 |
Skin Therapy Lett. |
pmid:22358305
|
Jiang G et al. |
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. |
2015 |
PLoS Pathog. |
pmid:26225771
|
Damps T et al. |
The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment. |
2017 |
PLoS ONE |
pmid:28859143
|
Erlendsson AM et al. |
Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice. |
2016 |
PLoS ONE |
pmid:27636884
|
Emmert S et al. |
Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate. |
2016 |
PLoS ONE |
pmid:27612149
|
Le TT et al. |
IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate. |
2016 |
PLoS ONE |
pmid:27100888
|
Song X et al. |
RasGRPs are targets of the anti-cancer agent ingenol-3-angelate. |
2013 |
PLoS ONE |
pmid:23991094
|
Lebwohl M et al. |
Ingenol mebutate gel for actinic keratosis. |
2012 |
N. Engl. J. Med. |
pmid:22417254
|
Freiberger SN et al. |
Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. |
2015 |
Mol. Cancer Ther. |
pmid:26116359
|